Abstract 183P
Background
The incidence of gastric cancer is particularly high in Iran, where it remains a leading cause of cancer-related death, and it is the most common cancer among Iranian men, with an ASR of 21.6 per 100,000 men (GLOBO2018). By contrast the incidence and mortalityof gastric cancer rank fifth and third respectively worldwide. The aim of this study was to evaluate the epidemiologic profile of gastric cancer in East Azerbaijan, Iran.
Methods
In total, 2 years of cancer registry data were collected from different sources in East Azerbaijan (EA-PBCR), and a data quality check was performed to ensure clean data. Using the 2000 World Health Organization standard population, we then generated age-standardized incidence rates (ASRs) for different cancers, with data were generated for each year from 1394 to 1395 of the Persian calendar (i.e., 19 March 2015 to 20 March 2016).
Results
In total we registered 1700 gastric cancer in two years; 918 cases in 2015 and 712 cases in 2016. From these, 1181 cases were male and 519 cases were female, and the male to female ratio was 2.28. The mean age of the patients was 68.45 (±12.97) years, with age range of 21-99 years old. The most common age group was 7th decade with 531 (31.2%) gastric cancer cases. The most common morphological types were adenocarcinoma (n = 667, 39.2%), and intestinal type carcinoma (n = 421, 24.8%), and signet ring cell carcinoma (n = 119, 7%). The age standardized incidence rate (ASR) was 29.65 and 13.30 in males and females per 100,000, in 2015. The ASR was 26.48 and 9.91 in males and females per 100,000, in 2016. Gastric Cancer account for 12.4% of all cancers in both sexes, and the odds for men was 1.50, compared with women (OR 1.50; 95% CI = 1.33 – 1.71). After rigorous attempts, 63.5 % of the cases had microscopic verification (MV), and we collected 3.3 % of reports based on clinical data. The remaining data were collected from the cause of death registry or autopsy records, producing a final DCO% of 27.4%.
Conclusions
The ASR was decreased from 29.7 to 26.48 in men, and decreased from 13.3 to 9.91 in female. However gastric cancer is the most common cancer in terms of incidence and mortality in East Azerbaijan, according to last results of EA-PBCR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract